Literature DB >> 9260290

CD6 recognizes the neural adhesion molecule BEN.

J E Skonier1, M A Bowen, A Aruffo, J Bajorath.   

Abstract

CD6 and its ligand activated leukocyte cell adhesion molecule (ALCAM, CD166) have been detected on various immune cells and in the brain. CD6-ligand interactions have been implicated in the regulation of T cell function. ALCAM shares the same extracellular domain organization and significant sequence homology with the chicken neural adhesion molecule BEN. Although ALCAM's CD6 binding site is only partially conserved in BEN, CD6 specifically binds BEN, albeit with approximately 10-fold lower avidity than ALCAM. Differences in binding avidity are not detected when ALCAM and BEN fusion proteins containing the full-length extracellular regions are tested. Homotypic interactions between full-length forms are likely to account for these observations. The identified cross-species interaction between CD6 and BEN suggests that CD6-ligand interactions are highly conserved.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260290      PMCID: PMC2143770          DOI: 10.1002/pro.5560060818

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  14 in total

1.  Expression of the CD6 T lymphocyte differentiation antigen in normal human brain.

Authors:  B Mayer; I Funke; B Seed; G Riethmüller; E Weiss
Journal:  J Neuroimmunol       Date:  1990 Sep-Oct       Impact factor: 3.478

2.  Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding.

Authors:  M A Bowen; J Bajorath; M D'Egidio; G S Whitney; D Palmer; J Kobarg; G C Starling; A W Siadak; A Aruffo
Journal:  Eur J Immunol       Date:  1997-06       Impact factor: 5.532

3.  DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension.

Authors:  F R Burns; S von Kannen; L Guy; J A Raper; J Kamholz; S Chang
Journal:  Neuron       Date:  1991-08       Impact factor: 17.173

4.  The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site.

Authors:  G S Whitney; G C Starling; M A Bowen; B Modrell; A W Siadak; A Aruffo
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

5.  Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes.

Authors:  R M Gangemi; J A Swack; D M Gaviria; P L Romain
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

Review 6.  The immunoglobulin superfamily--domains for cell surface recognition.

Authors:  A F Williams; A N Barclay
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

7.  2H1--a novel antigen involved in T lymphocyte triggering.

Authors:  C Morimoto; C E Rudd; N L Letvin; M Hagan; S F Schlossman
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

8.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.

Authors:  M A Bowen; D D Patel; X Li; B Modrell; A R Malacko; W C Wang; H Marquardt; M Neubauer; J M Pesando; U Francke
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

9.  The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins.

Authors:  A Aruffo; M B Melnick; P S Linsley; B Seed
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

10.  Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells.

Authors:  D D Patel; S F Wee; L P Whichard; M A Bowen; J M Pesando; A Aruffo; B F Haynes
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  1 in total

1.  ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells.

Authors:  Karry M Jannie; Christopher S Stipp; Joshua A Weiner
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.